Harrow Health (HROW)

Executive Summary

Harrow Health (NASDAQ: HROW) is a U.S.-based ophthalmic pharmaceutical company focused on developing, acquiring, and commercializing prescription eye care products. Through strategic acquisitions, including the recent addition of Iheejo (a non-steroidal anti-inflammatory) and Triamcinolone Acetonide injectable suspension, Harrow has built a diversified portfolio of commercial and late-stage assets. The company’s revenue growth has accelerated, driven by expanding sales of existing products and the launch of newly acquired drugs. Harrow’s strategy emphasizes identifying undervalued ophthalmic assets and maximizing their potential via a specialized sales force and targeted marketing. With an aging population and rising prevalence of eye diseases, the company is well-positioned to capture market share. Its pipeline includes early-stage candidates, but near-term growth hinges on continued acquisition execution and commercialization of recently approved products.

Upcoming Catalysts (preview)

• Q3 2026Launch and revenue ramp of Iheejo90% success
• Q4 2026Acquisition of additional late-stage ophthalmic assets60% success
• Q1 2027FDA approval of new ophthalmic drug application (e.g., generic or branded)70% success